Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: A French payer perspective.
CONCLUSION: This study suggests that the use of dabigatran in French atrial fibrillation patients is cost-effective, according to usually accepted thresholds.
PMID: 24973113 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - Category: Cardiology Authors: Chevalier J, Delaitre O, Hammès F, de Pouvourville G Tags: Arch Cardiovasc Dis Source Type: research
More News: Atrial Fibrillation | Cardiology | Cardiovascular | Coumadin | Heart | Heart Attack | Hemorrhagic Stroke | Ischemic Stroke | Pradaxa | Stroke | Study | Vitamin K | Vitamins | Warfarin